If you typed Southern Star Research into a search box, you are probably building a CRO shortlist. This article uses only what Southern Star Research publishes (southernstarresearch.com) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.
What Southern Star Research publishes
Southern Star Research is a Sydney CRO founded in 2010 that runs full-service Phase I–IV work, positioned around early-phase biotech plus medical device clients. It claims 4–8 week start-up through Phase I unit relationships. Lloyd Prescott is CEO and Dr David Lloyd is founder and Managing Director. We found no named sponsor first-in-human press release on its site.
Southern Star Research vs bioaccess®
| Dimension | Southern Star Research | bioaccess® |
|---|---|---|
| Core focus | Boutique Australian Phase I–IV CRO | First-in-human and early feasibility studies for medical devices |
| Geography | Australia | Latin America, since 2010 |
| Device FIH track record | No named device first-in-human study found on the public pages reviewed | Published case studies on bioaccessla.com |
| After the trial | See provider site | Live multi-country sanitary registration and in-country holder service |
Where each one fits
If you are a seed-to-Series B sponsor wanting an Australian specialist rather than a large CRO, Southern Star is a fair choice.
If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Southern Star Research, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.
Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not Southern Star Research features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.
Ready to compare a proposal? Request a first-in-human study proposal.
Competitor facts from the Southern Star Research public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.
Leave a Reply